Molecular Partners AG (MOLN) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic...

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in...

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG...

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as...

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T...

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile...

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of...

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement...

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have...